Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Ferreira

Neurology with Special Qualifications in Child Neurology Tampa, FL Medical Doctor

NPI 1861433559 CMS profile 84430

508 S Habana Ave, Suite 340, Tampa, FL 33609

Open in the dashboard

General payments

$87,783

837 records reported · program years 2019–2025

Research payments

$6,179

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$788,285 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jose Ferreira of Tampa, FL is reported in the CMS Open Payments database as having received $87,783 across 837 general payments and $6,179 in research payments paid to them. Separately, studies naming them as principal investigator received $788,285 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,639 137
2024 General $9,119 100
2023 General $2,598 89
2022 General $2,821 112
2021 General $3,210 128
2020 General $6,942 71
2019 General $57,454 200
2019 Research $6,179 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Ferreira
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Jose Ferreira were reported at $5,639. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Jose Ferreira Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $57,454 $262 $68–$1,313 $163
2020 $6,942 $188 $46–$1,222 $114
2021 $3,210 $183 $45–$1,356 $132
2022 $2,821 $229 $72–$1,177 $149
2023 $2,598 $269 $93–$1,195 $160
2024 $9,119 $300 $98–$1,428 $164
2025 $5,639 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eisai Inc. $22,272 58 payments
  2. Aquestive Therapeutics, Inc. $21,351 47 payments
  3. Greenwich Biosciences, Inc. $8,282 22 payments
  4. UCB, Inc. $8,190 156 payments
  5. Supernus Pharmaceuticals, Inc. $5,265 94 payments
  6. LivaNova USA, Inc. $4,810 15 payments
  7. Sunovion Pharmaceuticals Inc. $3,683 54 payments
  8. ACADIA Pharmaceuticals Inc $2,749 14 payments
  9. Jazz Pharmaceuticals Inc. $2,346 59 payments
  10. H. Lundbeck A S $1,703 4 payments
  11. Other $7,131 314 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,360 26 payments
  2. Food and Beverage $19,778 772 payments
  3. Travel and Lodging $9,128 30 payments
  4. Consulting Fee $3,500 1 payment
  5. Education $17 8 payments
Products named General payments · program years 2019–2025
  1. Fycompa $22,272 58 payments
  2. SYMPAZAN $21,351 47 payments
  3. Epidiolex $10,308 76 payments
  4. Fintepla $6,191 54 payments
  5. APTIOM $3,880 66 payments
  6. VNS Therapy $3,691 5 payments
  7. DAYBUE $2,749 14 payments
  8. Briviact $1,078 58 payments
  9. Azstarys $652 27 payments
  10. VALTOCO $635 9 payments
  11. Other $8,301 407 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $6,179 12 payments

Records

849 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record